Status: Recruiting
A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients
This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis \[SJIA\] and adult-onset Still's disease \[AOSD\]) that received canakinumab for at least 6 months.
Participants needed: 160
Trial details
Age: 1+Biological sex: AllType: ObservationalSponsor: Novartis PharmaceuticalsUpdated: Jun 9, 2026Locations: 1
Eligibility criteria
Pediatric or adult patients who were prescribed canakinumab before October 2021... [+1]